A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions

• Published in: JNCI : Journal of the National Cancer Institute Vol. 92; no. 5; pp. 418 - 423
• Main Authors: Mehta, R G, Williamson, E, Patel, M K, Koeffler, H P
• Format: Journal Article
• Language: English
• Published: United States 01.03.2000
• Subjects: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents - pharmacology; Antineoplastic Agents - pharmacology; Carcinogens; Chromans - pharmacology; Estradiol - pharmacology; Female; Ligands; Mammary Glands, Animal - drug effects; Mammary Glands, Animal - pathology; Mammary Neoplasms, Experimental - chemically induced; Mammary Neoplasms, Experimental - prevention & control; Mice; Mice, Inbred BALB C; Organ Culture Techniques; Precancerous Conditions - chemically induced; Precancerous Conditions - prevention & control; Progesterone - pharmacology; Receptors, Cytoplasmic and Nuclear - drug effects; Receptors, Cytoplasmic and Nuclear - physiology; Receptors, Retinoic Acid - drug effects; Receptors, Retinoic Acid - physiology; Retinoic Acid Receptor alpha; Retinoic Acid Receptor gamma; Retinoid X Receptors; Retinoids - pharmacology; Thiazoles - pharmacology; Thiazolidinediones; Transcription Factors - drug effects; Transcription Factors - physiology; Tretinoin - pharmacology; Troglitazone

Chemoprevention of breast cancer is an active area of investigation. Recent in vivo and in vitro studies have shown that thiazolidinediones (e.g., troglitazone) and retinoids are able to inhibit the growth of breast cancer cells. Troglitazone mediates its action via peroxisome proliferator-activated...